Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study

This article was originally published here

The independent and NIH-appointed Data Safety Monitoring Board (DSMB) revealed that the mRNA-1273 candidate has demonstrated an efficacy rate of 94.5% in the first interim analysis of the

The post Moderna’s Covid-19 vaccine candidate shows 94.5% efficacy in phase 3 COVE study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply